The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Loretta NastoupilThe virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Loretta J. Nastoupil, MD Anderson Cancer Center, Houston, US, discusses how to treat early relapse in a patient with follicular lymphoma (FL).
How to treat early relapse in a patient with FL
Nastoupil begins by outlining a clinical case and the benefits of utilizing PET scans to exclude transformation as the driver of poor outcomes. The presentation then reviews therapeutic options and the data that inform treatment selection, including data from the GADOLIN, AUGMENT, GALEN, and SWOG trials. Finally, Nastoupil describes how she would approach this case, utilizing available clinical trials that employ novel agents, such as tazemetostat and tafasitamab, and she offers insight for those that practice in a different setting.